NDAORALTABLET
Approved
Jun 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TRANXENE SD (clorazepate dipotassium) by PharmaIN is clinical pharmacology pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1972.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRANXENE SD (clorazepate dipotassium) is an oral benzodiazepine tablet approved in 1972 for short-term relief of anxiety disorders. It works by depressing central nervous system activity, with rapid decarboxylation to nordiazepam (the active metabolite) which has a 40-50 hour half-life and undergoes hepatic metabolism and urinary excretion.
LOE Approaching
As LOE approaches, the brand team will shift focus to lifecycle extension, generic competitive strategy, and cost-containment initiatives rather than growth-oriented commercial expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. The serum half-life is about 2 days. The drug is…
Indications (3)
Worked on TRANXENE SD at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.